Crinetics Pharmaceuticals (CRNX) News Today

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) is rising sharply after Vertex Pharmaceuticals announced a definitive all-cash acquisition of the company for $85.00 per share, valuing Crinetics at about $10 billion. The deal is the main driver behind the stock’s move, as investors are pricing in the takeover premium and the likelihood of a near-term closing. The transaction is expected to close in the current quarter, subject to customary approvals.

Analyst commentary also reinforced the move, with multiple firms lifting price targets to $85, essentially matching the deal price. That said, the stock is also seeing some caution around the transaction, including:

• Positive Sentiment: Vertex agreed to acquire Crinetics in an all-cash deal at $85 per share, creating a clear takeover premium for CRNX shareholders. Vertex to Acquire Crinetics Pharmaceuticals
• Positive Sentiment: JonesTrading, Jefferies, and Robert W. Baird all raised or reaffirmed targets at $85, signaling Wall Street now sees the stock near the deal value. Analyst updates via Benzinga
• Neutral Sentiment: Unusual options activity showed heavy put buying, which may reflect traders hedging uncertainty around deal completion or timing.
• Negative Sentiment: Law firms have begun investigating whether Crinetics’ board secured a fair price for shareholders, which could add legal noise around the acquisition. Shareholder Notice: Brodsky & Smith Investigation

In short, CRNX is up because of the announced Vertex buyout, with analyst upgrades and repeated $85 price targets reinforcing the takeover valuation. The legal investigations and put-buying are secondary concerns, but they do not appear to be outweighing the acquisition news today.